<?xml version="1.0" encoding="UTF-8"?>
<p>We also investigated sera obtained from volunteers who were 18–20 years old in the fall of 2005, before and 21 days after vaccination with seasonal trivalent live influenza vaccine (LAIV) 2005–2006. The trivalent vaccine was manufactured by “Microgen” (Irkutsk, Russia) and contained A/17/New Caledonia/99/145(H1N1), A/17/California/04/06(H3N2), and B/60/Jilin/01/1 (B/Yamagata-like) [
 <xref rid="B17-antibodies-09-00020" ref-type="bibr">17</xref>].
</p>
